Reissue Patent Claims Not Clearly and Unequivocally Supported in Original Patent Are Invalid
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
FORUM US, INC. v. FLOW VALVE, LLC
Before Reyna, Schall and Hughes. Appeal from the U.S. District Court for the Western District of Oklahoma.
Summary: The original patent on which a broadening reissue patent is based must clearly and unequivocally disclose the invention claimed in the reissue patent.
Forum filed a declaratory judgment action to invalidate a reissue patent owned by Flow Valve. The original patent claimed a fixture with “a plurality of arbors,” and the reissue patent added new claims without the arbor limitation. Forum contended the added reissue claims violated 35 U.S.C. § 251, because the original patent did not disclose an invention without arbors. In opposition, Flow Valve argued that a person of ordinary skill in the art would understand that the original patent disclosed multiple inventions, consisting of embodiments with and without arbors. Flow Valve supported this argument with an expert declaration. The district court granted summary judgment of invalidity because the original patent did not “explicitly and unequivocally” indicate the invention claimed in the reissue claims. Flow Valve appealed.
Affirming the grant of summary judgment, the Federal Circuit stated that the original patent must “clearly and unequivocally” disclose the newly claimed invention to satisfy § 251, and found that Flow Valve’s original patent did not disclose any arbor-less embodiment. The Federal Circuit added that even if a person of ordinary skill in the art would understand that the newly claimed, arbor-less invention would be possible, that understanding would be insufficient to comply with the standard set forth in the case law.
Editor: Paul Stewart
Written by: Nathan J. Lee & Jeremy Anapol
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…